If you're confused by the sudden ubiquity of CBD and cannabis-based products, you're not the only one. "My state doesn't even allow medical marijuana," Idahoans or South Dakotans may say. "So why can I suddenly walk into my local Sephora and buy cannabis oil mascara?" As you can imagine, it's complicated. And claims that CBD is 100% legal in all 50 states (which appear frequently) are oversimplifying the matter. Click Here For CBD
Researchers think that CBD interacts with receptors in your brain and immune system. Receptors are tiny proteins attached to your cells that receive chemical signals from different stimuli and help your cells respond. This creates anti-inflammatory and painkilling effects that help with pain management. This means that CBD oil may benefit people with chronic pain, such as chronic back pain.
It likely comes down to neurotransmitters in the brain. “One mechanism of action is that it de-sensitizes a particular receptor known to be involved in pain, called TRPV1,” Craft explains. TRPV1 creates that sort of burning sensation pain you might feel from something like nerve damage. As Craft points out, that’s only one particular form of pain that CBD could affect—and one in which scientists are still trying to learn more about.
Currently, the U.S. National Library of Medicine lists just 25 clinical studies involving CBD and its effects on pain. Only a handful of those have been completed so far, but there are more in the works. Many of these trials involve pain in people with advanced cancer, and while some show positive pay-offs, others demonstrate that cannabis treatment doesn’t provide any more relief than a placebo. The catch: Most of this science involves both CBD and THC (or Δ9-tetrahydrocannabinol, the part of cannabis that does give you a high).
I have a brother in law who has been diagnosed with cataplexy and narcoplexy, where he starts quivering and slowly loses control of his body and goes into a sleep, which causes him to drop to the ground with mild seizures while he is out. He lives alone (59 years old), but has smoked cannabis since he (we) were teenagers. He still smokes, and is on medication twice a day for this condition, but if he misses those meds by even half an hour, he is at risk of these seizures. The sad part is, these seizures are usually brought on by the smallest emotional change, usually tension, excitement or, the worst thing, if something he finds funny and is the least bit tickled about and starts to laugh, this process will immediately begin. Does anyone know if this kind of condition is treatable with cbd oil’s or concentrates? As I said, he smokes weed, and often grows his own, but he does it for the high and relaxation advantage, since he is basically home-bound due to this condition ending his work career about 4 years ago. Thanks for any replies. I’d be overjoyed if I could tell him there’s a possible solution to the problem other than his prescriptions. Or even if it worked WITH his meds to keep from having to live such a sedentary life.
CBD stands for cannabidiol, one of the major constituents of cannabis. CBD products are made from industrial hemp and come in various forms. Although hemp and cannabis are in the same plant species, CBD products now on the market contain less than 0.3 percent THC (tetrahydrocannabinol), the cannabis compound that gets you high. CBD oil can be mixed into food, either straight or diluted with cooking oil, or it can be heated and its vapors inhaled. You can buy CBD in capsules, liquids, gummies, and sublingual sprays, and it is added to tea, coffee, and smoothies. Business experts estimate that the market for CBD products will reach more than $2 billion in consumer sales in the U.S. within the next four years.
My dad has severe advanced stage Dementia. Will CBD oil help him at this point? He is now refusing to eat any solid food, but will accept most drinks.In addition, he has lost a great deal of weight even though they're giving him Mega Shakes containing a full meals worth of proteins, etc. He gets at least 4 of these a day..some which he refuses. Is his Dementia too far gone for CBD oils to help him?
To make matters more confusing, nine states (including California, Washington, and Colorado) let residents buy cannabis-based products with or without THC. Nearly two dozen other “medical marijuana states” allow the sale of cannabis, including capsules, tinctures, and other items containing CBD or THC, at licensed dispensaries to people whose doctors have certified that they have an approved condition (the list varies by state but includes chronic pain, PTSD, cancer, autism, Crohn’s disease, and multiple sclerosis). Sixteen more states legalized CBD for certain diseases. But because all these products are illegal according to the federal government, cannabis advocates are cautious. “By and large, the federal government is looking the other way,” says Paul Armentano, deputy director of the Washington, DC–based National Organization for the Reform of Marijuana Laws (NORML), but until federal laws are changed, “this administration or a future one could crack down on people who produce, manufacture, or use CBD, and the law would be on its side.”
The glutamatergic system is integral to development and maintenance of neuropathic pain, and is responsible for generating secondary and tertiary hyperalgesia in migraine and fibromyalgia via NMDA mechanisms (Nicolodi et al 1998). Thus, it is important to note that cannabinoids presynaptically inhibit glutamate release (Shen et al 1996), THC produces 30%–40% reduction in NMDA responses, and THC is a neuroprotective antioxidant (Hampson et al 1998). Additionally, cannabinoids reduce hyperalgesia via inhibition of calcitonin gene-related peptide (Richardson et al 1998a). As for Substance P mechanisms, cannabinoids block capsaicin-induced hyperalgesia (Li et al 1999), and THC will do so at sub-psychoactive doses in experimental animals (Ko and Woods 1999). Among the noteworthy interactions with opiates and the endorphin/enkephalin system, THC has been shown to stimulate beta-endorphin production (Manzanares et al 1998), may allow opiate sparing in clinical application (Cichewicz et al 1999), prevents development of tolerance to and withdrawal from opiates (Cichewicz and Welch 2003), and rekindles opiate analgesia after a prior dosage has worn off (Cichewicz and McCarthy 2003). These are all promising attributes for an adjunctive agent in treatment of clinical chronic pain states.